

Hampig Raphael Kourie

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3593834/hampig-raphael-kourie-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

782
citations

14
h-index

25
g-index

111
ext. papers

1,033
ext. citations

3.2
avg, IF

5.1
L-index

#	Paper	IF	Citations
69	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.. <i>JCO Global Oncology</i> , 2022 , 8, e21007	2.7	0
68	Talazoparib in BRCA-mutated advanced breast cancer: is earlier better?. <i>Pharmacogenomics</i> , 2022 , 23, 487-492	2.6	
67	Knowledge and behavior of Lebanese parents regarding melanoma prevention in public and private school children.. <i>Melanoma Management</i> , 2021 , 8, MMT59	2.1	
66	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. <i>Pharmacogenomics</i> , 2021 , 22, 1237-1250	2.6	0
65	KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 168, 103524	7	0
64	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2021 ,	3.8	1
63	Will advanced cholangiocarcinoma become a targetable malignancy?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 159, 103233	7	2
62	Molecular profiling of basal cell carcinomas in young patients. <i>BMC Medical Genomics</i> , 2021 , 14, 187	3.7	4
61	Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?. <i>Pharmacogenomics</i> , 2021 , 22, 619-628	2.6	
60	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103169	7	5
59	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021 , 48, 100782	11.1	0
58	In reply to: incorporating teleoncology practices in the undergraduate medical curriculum. <i>Future Oncology</i> , 2021 , 17, 11-12	3.6	
57	YouTube as a source of information on breast cancer in the Arab world. <i>Supportive Care in Cancer</i> , 2021 , 29, 8009-8017	3.9	1
56	Molecular pathogenesis of hereditary lung cancer: a literature review. <i>Pharmacogenomics</i> , 2021 , 22, 791-803	2.6	0
55	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021 , 13, 953-964	3.8	1
54	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. <i>Immunotherapy</i> , 2021 , 13, 1053-1065	3.8	1
53	An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. <i>Leukemia Research Reports</i> , 2021 , 15, 100245	0.6	

52	The Opinion of Oncologists on the Practice of Hypnosis among Cancer Patients in Lebanon. <i>Complementary Therapies in Medicine</i> , 2020 , 53, 102534	3.5	
51	Acute myeloid leukemia transformed to a targetable disease. <i>Future Oncology</i> , 2020 , 16, 961-972	3.6	5
50	Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. <i>CNS Oncology</i> , 2020 , 9, CNS55	4	1
49	Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. <i>Pharmacogenomics</i> , 2020 , 21, 721-727	2.6	3
48	A rare case of acute myeloid leukemia with t(12;19)(q13;q13). <i>Leukemia Research Reports</i> , 2020 , 14, 100216	2.6	1
47	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020 , 21, 221-230	3.6	7
46	Treating cancer patients in times of COVID-19 pandemic: A virtual women cancers multidisciplinary meeting experience. <i>Bulletin Du Cancer</i> , 2020 , 107, 738-740	2.4	4
45	Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target. <i>Pharmacogenomics</i> , 2020 , 21, 957-962	2.6	
44	Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 150, 102972	7	111
43	Skin adverse events in recently approved targeted therapies in solid malignancies. <i>Future Oncology</i> , 2019 , 15, 331-343	3.6	3
42	Ocular and orbital side effects of ALK inhibitors: a review article. <i>Future Oncology</i> , 2019 , 15, 1939-1945	3.6	6
41	Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. <i>International Journal of Womens Health</i> , 2019 , 11, 431-437	2.8	61
40	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. <i>Future Oncology</i> , 2019 , 15, 1505-1524	3.6	10
39	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , 2019 , 11, 1409-1422	3.8	17
38	Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13045-e13045	2.2	
37	Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e13544-e13544	2.2	
36	Seizures in cancer patients: a vast spectrum of etiologies. <i>Future Neurology</i> , 2019 , 14, FNL30	1.5	
35	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. <i>Future Oncology</i> , 2019 , 15, 533-541	3.6	12

34	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. <i>Future Oncology</i> , 2018 , 14, 829-835	3.6	3
33	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. <i>Future Oncology</i> , 2018 , 14, 2097-2102	3.6	4
32	New developments in the management of head and neck cancer - impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018 , 14, 295-303	2.9	44
31	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , 2018 , 105, 857-861	2.4	3
30	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. <i>Future Oncology</i> , 2017 , 13, 1097-1103	3.6	1
29	Physical long-term side-effects in young adult cancer survivors: germ cell tumors model. <i>Current Opinion in Oncology</i> , 2017 , 29, 229-234	4.2	5
28	Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report. <i>Journal of Medical Case Reports</i> , 2017 , 11, 303	1.2	13
27	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. <i>Future Oncology</i> , 2017 , 13, 1999-2006	3.6	1
26	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. <i>Immunotherapy</i> , 2017 , 9, 647-657	3.8	15
25	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. <i>International Journal of Hematologic Oncology</i> , 2017 , 6, 105-111	1	1
24	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. <i>OncoTargets and Therapy</i> , 2017 , 10, 3363-3372	4.4	8
23	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3515-3515	2.2	3
22	Immunotherapies in sarcoma: Updates and future perspectives. <i>World Journal of Clinical Oncology</i> , 2017 , 8, 145-150	2.5	9
21	Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. <i>World Journal of Clinical Oncology</i> , 2017 , 8, 425-428	2.5	3
20	Efficacy and tolerability of second-line intra-arterial 5FU or mitomycin C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15061-e15061	2.2	
19	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016 , 34, 794-796	4.3	14
18	Does tumor side represent a relevant factor for prognosis and treatment decision in metastatic colorectal cancer?. <i>Colorectal Cancer</i> , 2016 , 5, 91-93	0.8	0
17	Is metastatic pancreatic cancer an untargetable malignancy?. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 297-304	3.4	7

16	Road map for pain management in pancreatic cancer: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 599-606	3.4	33
15	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10124-10130	5.6	19
14	Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 745-750	3.4	14
13	Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 2679-81	1.7	9
12	EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. <i>Cancer Epidemiology</i> , 2015 , 39, 1099-102	2.8	11
11	Successful eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, e23-4	2.4	3
10	Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy. <i>Case Reports in Ophthalmological Medicine</i> , 2015 , 2015, 142408	0.7	5
9	Anal cancer treatment: current status and future perspectives. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2294-302	5.6	39
8	Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. <i>Journal of Bone Oncology</i> , 2015 , 4, 77-9	4.5	8
7	EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e18506-e18506	2.2	2
6	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 3294-8	1.4	2
5	Optimum chemotherapy for the management of advanced biliary tract cancer. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4121-5	5.6	9
4	Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015 , 16, 5899-902	1.7	1
3	Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review. <i>Canadian Journal of Ophthalmology</i> , 2014 , 49, 450-7	1.4	28
2	Optimum chemotherapy in the management of metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2352-7	5.6	15
1	Outcome of breast cancer screening: a Lebanese single institution experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 9471-3	1.7	